Testosterone therapy should be disclosed before plastic surgery, but taking TRT does not automatically mean you must stop it. Testosterone can raise red blood cell levels, and the team needs to review your dose, formulation, recent labs, medical history, and prescriber's plan. Some testosterone also converts to estrogen, which can matter when evaluating breast gland enlargement. Do not change a prescription on your own to prepare for surgery.
Why does testosterone matter for surgical planning?
Testosterone can increase hematocrit, the proportion of blood made up of red blood cells. An elevated result needs clinical interpretation before elective surgery. Sleep apnea, smoking, dehydration, and other conditions can also influence the assessment; the answer is not simply to assume every abnormal value is from TRT.
Clot risk is assessed separately using your history, mobility, procedure length, and other factors. Studies of TRT and venous blood clots have produced uncertainty: a meta-analysis of randomized trials did not show a statistically significant increase, but could not exclude a clinically meaningful risk. That is not evidence that stopping TRT routinely improves every surgical outcome.
Testosterone is not an anticoagulant. A high hematocrit and a tendency to bleed are different issues, and both should be evaluated on their own merits rather than grouped together as “thin” or “thick” blood.
Which records and lab values are useful?
Bring the prescribed product, dose, route, schedule, and date of your last dose. Include injections, gels, or pellets, since their duration differs. The team may review a recent complete blood count, particularly hemoglobin and hematocrit, and request additional assessment based on your health and operation.
The Endocrine Society guideline emphasizes appropriate diagnosis and monitoring during testosterone treatment. A testosterone level alone does not replace review of blood counts, symptoms, and associated conditions. Any abnormal result should be addressed by the appropriate treating clinician.
| What you use or report | Why it matters | What to discuss |
|---|---|---|
| Prescribed replacement therapy | Formulation and monitoring affect the plan | Prescriber contact, dose history, recent labs |
| Nonprescribed anabolic steroids or stacked products | Contents, doses, and health effects may be less predictable | Full disclosure and medical evaluation before elective surgery |
| Elevated hematocrit or untreated sleep apnea | May require optimization | Whether further assessment should precede scheduling |
| Breast gland enlargement while using hormones | Hormonal stimulation may remain active | The cause and whether it is controlled before chest surgery |
Can TRT contribute to gynecomastia after surgery?
Hormonal balance can affect breast gland tissue, including through conversion of testosterone to estrogen. TRT does not cause gynecomastia in every patient, and not all chest fullness is gland. The guide to gynecomastia versus chest fat separates the anatomical question.
Gynecomastia surgery reshapes existing tissue; it does not treat the hormonal driver. If stimulation continues, remaining gland can enlarge. Our article on gynecomastia recurrence explains why the medication and endocrine history belong in the plan. Do not add an estrogen-blocking medicine yourself to protect a surgical result.
Should I stop or change my dose before surgery?
The surgeon, anesthesia team, and prescribing clinician should coordinate that decision. Continuing, adjusting, or delaying treatment may depend on findings, and some long-acting preparations cannot be managed like a daily tablet. Skipping a dose without guidance does not guarantee that a relevant risk has resolved.
Use the same disclosure approach for other prescriptions, including GLP-1 medicines before anesthesia. They have different mechanisms and should not inherit a testosterone plan or a generic stop list.
Coordinate the hormone plan before the surgical date
Give Dr. Ruben Castro your medication and lab history early enough to consult with the prescriber when needed. The goal is a clear, written plan for the operation, relevant testing, and any medication changes. Honest disclosure of both prescribed and nonprescribed products makes that plan more reliable.
